Compare DIN & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIN | AQST |
|---|---|---|
| Founded | 1958 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 446.6M | 521.0M |
| IPO Year | 1994 | 2007 |
| Metric | DIN | AQST |
|---|---|---|
| Price | $28.10 | $4.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $29.67 | $9.00 |
| AVG Volume (30 Days) | 380.5K | ★ 1.9M |
| Earning Date | 05-06-2026 | 03-04-2026 |
| Dividend Yield | ★ 2.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.11 | N/A |
| Revenue | ★ $879,300,000.00 | $67,430,000.00 |
| Revenue This Year | $3.61 | $14.23 |
| Revenue Next Year | $0.41 | $58.36 |
| P/E Ratio | $25.40 | ★ N/A |
| Revenue Growth | ★ 8.25 | 0.77 |
| 52 Week Low | $18.63 | $2.20 |
| 52 Week High | $39.68 | $7.55 |
| Indicator | DIN | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 35.69 | 46.55 |
| Support Level | $27.52 | $3.69 |
| Resistance Level | $28.64 | $4.46 |
| Average True Range (ATR) | 1.18 | 0.21 |
| MACD | -0.17 | -0.01 |
| Stochastic Oscillator | 13.71 | 23.44 |
Dine Brands Global Inc owns and franchises thousands of restaurants under the Applebee's and International House of Pancakes names. Almost all company restaurants are located in the United States and franchised. Royalty revenue, which the company gets from franchisees based on franchisees' sales, accounts for roughly three-quarters of total company revenue. The company also earns revenue by leasing restaurant sites to franchisees. The company has four reportable segments Franchise operations, (an aggregation of Applebee's and IHOP franchise operations), Rental operations, Financing operations and Company-operated restaurant operations. The majority of revenue is derived from the Franchise operations segment.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.